5 Things You’ll Want to Know From the World’s Biggest Marijuana Biotech


Pixabay / freeGraphicToday / CC0 Creative Commons

Anticipation is building for GW Pharmaceuticals (NASDAQ:GWPH) as the biotech prepares to hopefully launch its first product in the U.S. in 2018. The company announced its fiscal 2018 first-quarter results after the market closed on Monday. Frankly, most investors weren’t too interested in the financial numbers. But there was definitely a desire to know more about what is going on with the potential launch of Epidiolex and GW’s cannabinoid pipeline.

View Original Article Here

Repost is the designation for articles collected from the Internet whose content may interest our readers. These articles are not written by our staff and they do not necessarily reflect our views.

Related posts